HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and raises the price target from $11 to $12.
May 10, 2024 | 7:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Coherus BioSciences and increased the price target from $11 to $12, indicating a positive outlook on the stock.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100